Research progress in immunotherapy for resectable non-small cell lung cancer
- VernacularTitle:可切除非小细胞肺癌免疫治疗的研究进展
- Author:
Hao YANG
1
;
Chengcheng ZHANG
1
;
Yue ZHANG
1
;
Liwen ZHANG
1
;
Maoyong FU
1
Author Information
1. Department of Thoracic Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, Sichuan, P. R. China
- Publication Type:Journal Article
- Keywords:
Resectable non-small cell lung cancer;
immunotherapy;
neoadjuvant therapy;
review
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2025;32(11):1664-1671
- CountryChina
- Language:Chinese
-
Abstract:
Resectable non-small cell lung cancer (NSCLC) is prone to recurrence and metastasis after simple surgery. Although patients can benefit from preoperative neoadjuvant chemotherapy and postoperative adjuvant chemotherapy, the 5-year survival rate is not significantly improved. In recent years, with the rise of immunotherapy, NSCLC immunotherapy has gradually received attention. Many explorations have been made on resectable NSCLC immunotherapy, and satisfactory results have been obtained. With the release of multiple phase 3 research results, a new chapter in resectable NSCLC immunotherapy has officially opened. However, there are still many problems in the immunotherapy of resectable NSCLC. This article reviews the current relevant research and provides reference for clinical application.
